Rates of efficacy by treatment and time point
| Hours after infusion (N) . | FEIBA, % . | NovoSeven, % . | 90% confidence interval, %* . | P . |
|---|---|---|---|---|
| 2† (48) | 75.0 | 60.4 | −0.73-29.90 | .482 |
| 6 (47) | 80.9 | 78.7 | −11.42-15.67 | .059 |
| 12 (45) | 80.0 | 84.4 | −18.08-9.19 | .101 |
| 24 (42) | 95.2 | 85.7 | −1.29-20.33 | .202 |
| 36 (41) | 100.0 | 90.2 | 2.13-17.38 | .129 |
| 48 (41) | 97.6 | 85.4 | 2.05-22.34 | .325 |
| Hours after infusion (N) . | FEIBA, % . | NovoSeven, % . | 90% confidence interval, %* . | P . |
|---|---|---|---|---|
| 2† (48) | 75.0 | 60.4 | −0.73-29.90 | .482 |
| 6 (47) | 80.9 | 78.7 | −11.42-15.67 | .059 |
| 12 (45) | 80.0 | 84.4 | −18.08-9.19 | .101 |
| 24 (42) | 95.2 | 85.7 | −1.29-20.33 | .202 |
| 36 (41) | 100.0 | 90.2 | 2.13-17.38 | .129 |
| 48 (41) | 97.6 | 85.4 | 2.05-22.34 | .325 |
Efficacy is defined as effective or partially effective by patient rating. The 6-hour time point is the primary outcome.
The 90% confidence interval for the difference in the proportions of patients' rating of efficacy for each of the treatments (columns 2 and 3). Rejecting the null hypothesis at the .05 level is equivalent, in this setting, to showing that the upper and lower limits of the confidence interval for the difference in efficacy fall within plus or minus 15%.
Prior to the second dose of NovoSeven.